ARCHIVES

Funding Opportunities. (8-page issue).

This article is from The Cancer Letter archive.

Vol. 29 No. 18 | May 2, 2003

Download PDF Visit The Full Archive

Related Articles

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

March 30, 2012

Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.

February 15, 2002

Diagnosis-Treatment Cidac contract Gets Recompetition Okay

December 16, 1983

FDA Ponders Standards For “Retrospective Prospective” Studies

January 30, 2009

Medicare coverage and quality of care top ASCO’s list of policy priorities for 2004.

February 27, 2004

NCI-Approved Clinical Trials

May 30, 2003